NeueHealth Q2 2025 results: Revenue missed at $209.1M vs. $300.8M estimate, but EPS beat at -$1.68 vs. -$4.39. Adjusted EBITDA profitable for sixth straight quarter. Stock dipped slightly pre-market.
NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today reported financial results for its second quarter ended June 30, 2025.
NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE), the value-driven healthcare company, today announced it will report second quarter financial results before the financial markets open on Thursday, August 7, 2025, followed by a conference call at 8:00 AM Eastern Time.
NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today reported financial results for its first quarter ended March 31, 2025.
NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE), the value-driven healthcare company, today announced it will report first quarter financial results before the financial markets open on Thursday, May 8, 2025, followed by a conference call at 8:00 AM Eastern Time.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NeueHealth, Inc. (NYSE: NEUE) to an affiliate of New Enterprise Associates. Under the terms of the proposed transaction, shareholders of NeueHealth will receive $7.33 in cash for each share of NeueHealth that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today reported financial results for its fourth quarter and full year ended December 31, 2024.
NeueHealth, Inc. ("NeueHealth") (NYSE: NEUE), the value-driven healthcare company, today announced it will report fourth quarter and full year 2024 financial results before the financial markets open on Thursday, March 20, 2025, followed by a conference call at 8:00 AM Eastern Time.
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NeueHealth, Inc. (NYSE: NEUE) to an affiliate of New Enterprise Associates. Under the terms of the proposed transaction, shareholders of NeueHealth will receive $7.33 in cash for each share of NeueHealth that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
BALA CYNWYD, Pa., Jan. 03, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
NEW YORK, Jan. 03, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
NEW YORK, Dec. 28, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors in NeueHealth, Inc. (“NeueHealth” or “the Company”) (NYSE: NEUE) for potential breaches of fiduciary duty on the part of its directors and management.
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of NeueHealth, Inc. (NYSE: NEUE) to an affiliate of New Enterprise Associates for $7.33 per share in cash is fair to NeueHealth shareholders.
NeueHealth, Inc. (“NeueHealth” or the “Company”) (NYSE: NEUE), the value-driven healthcare company, today announced that it has entered into a definitive merger agreement pursuant to which the Company will be acquired by an affiliate of New Enterprise Associates (“NEA”) at an enterprise value of approximately $1.3 billion. Upon completion of the transaction, NeueHealth will become a privately held company with the flexibility and resources to continue advancing its value-driven, consumer-centric care model.
